Gain Therapeutics, Inc. (GANX)

US — Healthcare Sector
Peers: BIVI  INAB  NAMS  CUE  TFFP  LIFE  LTRN    ELYM  INBX  MACK  CELC  ELVN  MOLN  MNOV  ANEB  CSBR  CYT 

Automate Your Wheel Strategy on GANX

With Tiblio's Option Bot, you can configure your own wheel strategy including GANX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GANX
  • Rev/Share 0.0
  • Book/Share 0.2015
  • PB 8.7847
  • Debt/Equity 0.031
  • CurrentRatio 2.2177
  • ROIC -3.1079

 

  • MktCap 53003712.0
  • FreeCF/Share -0.5337
  • PFCF -3.4621
  • PE -2.4262
  • Debt/Assets 0.0154
  • DivYield 0
  • ROE -2.4756

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation GANX Scotiabank -- Sector Outperform -- $12 March 7, 2025
Initiation GANX ROTH MKM -- Buy -- $7 Dec. 6, 2024

News

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders
GANX
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity

Read More
image for news Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
GANX
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present and participate in one-on-one meetings at The Citizens Life Sciences Conference, being held May 7th-8th in New York City, NY.

Read More
image for news Gain Therapeutics to Participate at The Citizens Life Sciences Conference
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders
GANX
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral poster presentation at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease and Related Disorders, being held May 7th-10th in New York City, NY.

Read More
image for news Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
GANX
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025 First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025

Read More
image for news Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

About Gain Therapeutics, Inc. (GANX)

  • IPO Date 2021-03-19
  • Website https://www.gaintherapeutics.com
  • Industry Biotechnology
  • CEO Mr. Gene Mack M.B.A.
  • Employees 23

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.